EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the Vim–PGI 2 Pathway Enhances CD8 + T Cell‐Mediated Antitumor Immunity in Breast Cancer

Hong Quan iD, Lujing Shao iD, Qi Li iD, Chunyan Dong iD

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/8880918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 28.04.2026. Verfasst von Hong Quan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai East Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China, njmu.edu.cn. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Breast Neoplasms. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Pudong New Area Health Commission, Shanghai Municipal Health Commission, Tongji University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most prevalent malignancy in women, and the limited effectiveness of current treatments highlights the need for novel immune regulatory mechanisms to improve long‐term survival. This study investigated the role of Vim in PGI 2 synthesis and its impact on tumor immune regulation. Multiomics profiling revealed molecular alterations following Vim deletion, which were validated in murine breast cancer models using RT‐qPCR, Western blot, ELISA, and flow cytometry, with rescue experiments involving exogenous PGI 2 . The findings showed that Vim deletion downregulated arachidonic acid metabolism, reduced PTGIS expression, and significantly lowered PGI 2 levels. Functional assays demonstrated that Vim deficiency enhanced T cell‐mediated antitumor immunity, evidenced by an increased proportion of CD8 + T cells, upregulation of cytotoxic genes ( Ifng , Gzmb , Tnf , and Klrd1 ), and activation of inflammation‐related signaling pathways, as indicated by enhanced phosphorylation of ERK1/2 and p65. Both exogenous PGI 2 supplementation and ozagrel treatment reversed these effects. In conclusion, the Vim–PGI 2 axis is identified as a key regulator of CD8 + T cell immunity in breast cancer, representing a potential therapeutic target and a critical consideration in anticoagulant management during cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesBreast NeoplasmsAnimalsFemaleMiceHumansSignal TransductionGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

CD8+ T cell activationPGI2Vimarachidonic acid metabolismbreast cancer

Autor:innen und Institutionen

  • Shanghai East Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China, njmu.edu.cn.
  • Department of Breast surgery, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.
  • Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, China, tongji.edu.cn.

ORCID-Profile: Hong Quan, Lujing Shao, Qi Li, Chunyan Dong

Förderung

  • Shanghai Pudong New Area Health Commission
  • Shanghai Municipal Health Commission
  • Tongji University

Zitieren

APA

Quan, H., Shao, L., Li, Q., & Dong, C. (2026). Targeting the Vim–PGI 2 Pathway Enhances CD8 + T Cell‐Mediated Antitumor Immunity in Breast Cancer. Human Mutation, 2026(1). https://doi.org/10.1155/humu/8880918

Vancouver

Quan H, Shao L, Li Q, Dong C. Targeting the Vim–PGI 2 Pathway Enhances CD8 + T Cell‐Mediated Antitumor Immunity in Breast Cancer. Human Mutation. 2026;2026(1). doi:10.1155/humu/8880918

BibTeX
@article{Quan2026,
  author = {Quan, Hong and Shao, Lujing and Li, Qi and Dong, Chunyan},
  title = {Targeting the Vim–PGI 2 Pathway Enhances CD8 + T Cell‐Mediated Antitumor Immunity in Breast Cancer},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/8880918}
}
Kostenlos starten →